Targeting Medicines for Cardiology


Welcome to Milestone Pharmaceuticals Inc.


Milestone Pharmaceuticals Inc. (“Milestone”) is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone’s lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 2.